News | April 14, 2025
Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
The Atlan A100 system delivers advanced ventilation technology for adults, pediatric patients, and neonates, revolutionizing care with seamless workflows across hospital departments
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
Subscribe To Our Newsletter & Stay Updated
